- Conditions
- Neuropathic Corneal Pain
- Interventions
- Urcosimod ophthalmic solution is a preservative-free topical ophthalmic product; supplied in unit dose ampoules; administered QID for 12-weeks.
- Drug
- Lead sponsor
- Okyo Pharma Ltd
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 111 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2027
- U.S. locations
- 1
- States / cities
- Nashville, Tennessee
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 1–24
of 84
matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
- Conditions
- Dry Eye Syndromes, Dry Eye Disease, Kerato Conjunctivitis Sicca
- Interventions
- 5% Tavilermide ophthalmic solution, Vehicle ophthalmic solution
- Drug · Other
- Lead sponsor
- Mimetogen Pharmaceuticals USA, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 642 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2024
- U.S. locations
- 29
- States / cities
- Phoenix, Arizona • Glendale, California • Murrieta, California + 25 more
- Conditions
- Allergic Conjunctivitis
- Interventions
- Bromfenac, Placebo
- Drug
- Lead sponsor
- Bausch & Lomb Incorporated
- Industry
- Eligibility
- 10 Years and older
- Enrollment
- 90 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2006 – 2007
- U.S. locations
- 1
- States / cities
- Irvine, California
- Conditions
- Dry Eye Disease (DED)
- Interventions
- DFL24498, Vehicle
- Drug · Other
- Lead sponsor
- Dompé Farmaceutici S.p.A
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 417 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2027
- U.S. locations
- 24
- States / cities
- Chandler, Arizona • Azusa, California • Glendale, California + 21 more
- Conditions
- Healthy Volunteers
- Interventions
- USB005 (aclerastide) Ophthalmic Solution, USB005 Ophthalmic Solution Placebo
- Drug
- Lead sponsor
- US Biotest, Inc.
- Industry
- Eligibility
- 18 Years to 64 Years
- Enrollment
- 32 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2018 – 2019
- U.S. locations
- 1
- States / cities
- Cypress, California
- Conditions
- Dry Eye
- Interventions
- HL036 ophthalmic solution, Placebo vehicle solution
- Biological · Other
- Lead sponsor
- HanAll BioPharma Co., Ltd.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 150 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2018
- U.S. locations
- 2
- States / cities
- Lewiston, Maine • Andover, Massachusetts
- Conditions
- Glaucoma and Ocular Hypertension
- Interventions
- DE-117 Ophthalmic Solution, Timolol Maleate Ophthalmic Solution 0.5%
- Drug
- Lead sponsor
- Santen Inc.
- Industry
- Eligibility
- 12 Months and older
- Enrollment
- 426 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2020
- U.S. locations
- 47
- States / cities
- Phoenix, Arizona • Sun City, Arizona • Burbank, California + 40 more
- Conditions
- Dry Eye Disease
- Interventions
- Lifitegrast/Perfluorohexyloctane Fixed Dose Combination, Lifitegrast, Perfluorohexyloctane, Vehicle
- Drug
- Lead sponsor
- Bausch & Lomb Incorporated
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 443 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2026
- U.S. locations
- 32
- States / cities
- Phoenix, Arizona • Glendale, California • Long Beach, California + 27 more
- Conditions
- Dry Eye
- Interventions
- SDP-4 Ophthalmic Solution (0.1%), SDP-4 Ophthalmic Solution (1.0%), SDP-4 Ophthalmic Solution (3.0%), Vehicle
- Drug
- Lead sponsor
- Silk Technologies, Ltd.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 305 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019
- U.S. locations
- 26
- States / cities
- Azusa, California • Garden Grove, California • Mission Hills, California + 22 more
- Conditions
- Dry Eye Disease (DED)
- Interventions
- CyclASol Ophthalmic Solution
- Drug
- Lead sponsor
- Novaliq GmbH
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 202 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2022
- U.S. locations
- 14
- States / cities
- Los Angeles, California • Newport Beach, California • Carmel, Indiana + 11 more
- Conditions
- Open-angle Glaucoma, Ocular Hypertension
- Interventions
- DE-112, DE-112 Vehicle Solution, Timolol Maleate Solution
- Drug
- Lead sponsor
- Santen Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 147 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2011 – 2012
- U.S. locations
- 2
- States / cities
- Austin, Texas • San Antonio, Texas
- Conditions
- Diabetic Macular Edema
- Interventions
- nepafenac 0.1% drops, Nepafenac Vehicle
- Drug · Other
- Lead sponsor
- Jaeb Center for Health Research
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 125 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2011 – 2013
- U.S. locations
- 32
- States / cities
- Loma Linda, California • Palm Springs, California • Santa Barbara, California + 29 more
- Conditions
- Fuchs' Corneal Endothelial Dystrophy (FCED)
- Interventions
- Part A Elamipretide 1.0% Ophthalmic Solution, Part B Elamipretide 3.0% Ophthalmic Solution, Part A Placebo, Part B Placebo
- Drug
- Lead sponsor
- Stealth BioTherapeutics Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 22 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016 – 2018
- U.S. locations
- 2
- States / cities
- Edgewood, Kentucky • Boston, Massachusetts
- Conditions
- Diabetic Macular Edema
- Interventions
- Dexamethasone ophthalmic suspension (OCS-01), Vehicle
- Drug
- Lead sponsor
- Oculis
- Industry
- Eligibility
- 18 Years to 85 Years
- Enrollment
- 552 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2026
- U.S. locations
- 40
- States / cities
- Phoenix, Arizona • Springdale, Arkansas • Beverly Hills, California + 35 more
- Conditions
- Postoperative Complications, Cataract
- Interventions
- Bromfenac, Placebo
- Drug
- Lead sponsor
- Bausch & Lomb Incorporated
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 527 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2003 – 2004
- U.S. locations
- 39
- States / cities
- Birmingham, Alabama • Little Rock, Arkansas • Irvine, California + 34 more
- Conditions
- Retinopathy of Prematurity, Retinal Detachment, Blindness
- Interventions
- ACULAR, REFRESH TEARS, placebo
- Drug
- Lead sponsor
- University of South Alabama
- Other
- Eligibility
- 10 Days to 15 Days
- Enrollment
- 83 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2005 – 2008
- U.S. locations
- 1
- States / cities
- Mobile, Alabama
- Conditions
- Nonexudative Age-related Macular Degeneration
- Interventions
- MC-1101, Placebo
- Drug
- Lead sponsor
- MacuCLEAR, Inc.
- Industry
- Eligibility
- 50 Years to 85 Years
- Enrollment
- 20 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2013
- U.S. locations
- 1
- States / cities
- Artesia, California
- Conditions
- Open-angle Glaucoma, Ocular Hypertension
- Interventions
- Vehicle of DE-126 Ophthalmic Solution, high dose of DE-126 Ophthalmic Solution, Topical ultra-low dose of DE-126 Ophthalmic Solution, Topical low dose of DE-126 Ophthalmic Solution, Topical medium dose of DE-126 Ophthalmic Solution, Topical high dose of DE-126 Ophthalmic Solution, 0.005% Latanoprost Ophthalmic Solution
- Drug
- Lead sponsor
- Santen Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 241 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2018
- U.S. locations
- 12
- States / cities
- Artesia, California • Mission Hills, California • Newport Beach, California + 9 more
- Conditions
- Dry Eye Disease
- Interventions
- 0.003% AR-15512 ophthalmic solution, AR-15512 vehicle ophthalmic solution
- Drug
- Lead sponsor
- Aerie Pharmaceuticals
- Industry
- Eligibility
- 30 Years and older
- Enrollment
- 465 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2023
- U.S. locations
- 23
- States / cities
- Glendale, California • Torrance, California • Colorado Springs, Colorado + 19 more
- Conditions
- Dry Eye Disease
- Interventions
- CyclASol topical ocular, eye drops, Vehicle topical ocular, eye drops
- Drug
- Lead sponsor
- Novaliq GmbH
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 328 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2018
- U.S. locations
- 9
- States / cities
- Newport Beach, California • Torrance, California • Indianapolis, Indiana + 6 more
- Conditions
- Bacterial Conjunctivitis
- Interventions
- AzaSite, Vehicle
- Drug · Other
- Lead sponsor
- Merck Sharp & Dohme LLC
- Industry
- Eligibility
- 12 Months and older
- Enrollment
- 685 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2004 – 2006
- U.S. locations
- 32
- States / cities
- Flagstaff, Arizona • Cudahy, California • Petaluma and Santa Rosa, California + 27 more
- Conditions
- Inflammation, Pain
- Interventions
- Loteprednol etabonate, Vehicle of Loteprednol Etabonate
- Drug
- Lead sponsor
- Bausch & Lomb Incorporated
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 407 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2010
- U.S. locations
- 1
- States / cities
- Rochester, New York
- Conditions
- Allergic Conjunctivitis
- Interventions
- PR013 (0.045%), PR013 (0.06%), Vehicle
- Drug
- Lead sponsor
- Realm Therapeutics, Inc.
- Industry
- Eligibility
- 10 Years and older
- Enrollment
- 96 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2017 – 2018
- U.S. locations
- 1
- States / cities
- Philadelphia, Pennsylvania
- Conditions
- Healthy Volunteers, Dry Eye Syndromes
- Interventions
- AGN-232411, AGN-232411 Vehicle
- Drug
- Lead sponsor
- Allergan
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 77 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2015 – 2016
- U.S. locations
- 3
- States / cities
- Artesia, California • Glendale, California • Montebello, California